HOT OFF THE WIRE

Imperial Innovations IVO Veryan Medical appoints new COO and NEDs

  Imperial Innovations (IVO) - Veryan Medical appoints new COO and NEDs

RNS Number : 4578H
Imperial Innovations Group plc
11 July 2012




11 July 2012



Imperial Innovations Group plc



Veryan Medical Ltd makes new appointments to the Executive Management and to
the Board



Imperial Innovations Group plc (AIM: IVO, 'Innovations'), a leading technology
commercialisation and investment group, announces that its portfolio company,
Veryan Medical Ltd ("Veryan"), a specialist company in vascular disease, has
made an appointment to the Executive Management team and two further
appointments to the Board. Nick Yeo has been appointed as Chief Operating
Officer and Todd M. Pope and Jeffrey B. Jump appointed as Non-Executive
Directors.



Nick Yeo has over 20 years' international experience in the healthcare
industry. He began his career in pharmaceuticals, becoming CEO of Sterling
Winthrop Prescription Medicines, before moving on to senior marketing and
business leadership roles at Gensia Europe and Scotia QuantaNova. Before
joining Veryan he held senior management positions in product and clinical
development at oncology drug-device specialist Light Sciences, where he led
the formation of a cardiovascular technology start-up.



Todd M. Pope is President and CEO of TransEnterix, Inc., an emerging medical
device company. Prior to joining TransEnterix, he was the Worldwide President
of Cordis Corporation, part of Johnson & Johnson, and before then, he was
Chief Executive Officer of Liquidia Technologies. He has held roles of
increasing responsibilities in Sales and Marketing at Boston Scientific,
rising to Vice President, Global Sales and Marketing, Neurovascular Division.



Jeffrey B. Jump is President of interventional cardiology specialists
Biosensors. He is also currently on the board of BeneChill Inc., and PneumRx
Inc. Prior to joining Biosensors, Jeff was CEO of medical simulation
specialists Xitact, which was subsequently acquired by Mentice. Before this he
held senior management roles with several medical device companies, including
Embol-X Inc., Alliance Medical Technologies, Cardio Thoracic Systems (CTS),
Haemonetics S.A. and Pfizer Hospital Products
Group.




Commenting on the appointments, Susan Searle, CEO of Imperial Innovations plc,
said:



"Veryan is at a key stage in its development and evolution, and it is
therefore timely to add additional skills to the management and Board. Nick,
Todd and Jeffrey have a range of skills - from sales and marketing, to
clinical and regulatory - which will be very useful to Veryan as they prepare
their lead product, the BioMimics 3D™ stent technology, for regulatory
submission in Europe and potential commercialisation."



                                    -Ends-



Enquiries:



Imperial Innovations                  020 7594 6589
Susan Searle, Chief Executive Officer
Diana Crisp, PR Manager
College Hill                          020 7457 2020
Melanie Toyne Sewell/Tim Watson



Notes to editors



Imperial Innovations - www.imperialinnovations.co.uk



Innovations creates, builds and invests in pioneering university technologies
addressing global problems in healthcare, energy, engineering and the
environment. It combines deep understanding of science and technology with
commercial acumen and strong investment expertise.



Innovations supports scientist-entrepreneurs in the commercialisation of their
ideas by:



· leading the formation of new companies and providing facilities in the
early stages

· providing significant investment and encouraging co-investment to
accelerate the transition from R&D to products

· providing operational expertise

· helping to recruit high-calibre industry figures and experienced
entrepreneurs as executive management and Board members



Innovations invests in companies based on technologies from or associated with
four universities: Imperial College London; and Cambridge University, Oxford
University, and UCL supported by its collaborations with Cambridge Enterprise,
OSEM and UCL Business. These are the UK's leading research intensive
universities, measured by research income.



By raising £140 million in January 2011, Innovations has been able to
accelerate the making of, and increase the size of its investments. In the
year to 31 July 2011, Innovations invested £35.1 million (2010: £14 million)
in 23 ventures, and launched six new companies.



In its current portfolio of 78 companies, Innovations' most advanced assets
include Circassia, which develops innovative vaccines for the treatment of a
wide range of allergies; and Nexeon, a battery materials and licensing company
which develops silicon anodes which extend the life and increase the capacity
of lithium-ion batteries.



About Veryan



Veryan is developing innovative solutions to improve the performance of
vascular stents using the principles of biomimicry. Veryan's BioMimics 3D™
stent technology involves adapting traditional straight stent designs to a
three-dimensional helical shape, which more closely mimics the natural
geometry of the human vascular system. BioMimics 3D technology is designed to
improve clinical performance by improving flow conditions in, and
bio-mechanical performance of, stented vessels.



Pre-clinical studies have shown that BioMimics 3D stent technology may
significantly reduce restenosis (the narrowing of stented arterial segments)
and confer significant mechanical benefits: the BioMimics 3D stent is more
flexible, kink and fracture resistant than conventional counterparts.



Veryan has completed enrolment in a pivotal randomised study, MIMICS, and
intends to submit a CE Mark application for the BioMimics 3D stent later this
year.





                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


NRARBMJTMBIBBLT -0- Jul/11/2012 13:50 GMT